Aethlon medical treats first patient in australian hemopurifier® cancer trial

First patient enrolled and treated at the cancer clinical trial unit, calhn, royal adelaide hospital  aethlon advances hemopurifier® study in solid tumors not responding to anti-pd-1 antibodies san diego , jan. 29, 2025 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant  milestone: the treatment of the first patient with the hemopurifier in its australian safety, feasibility and dose-finding clinical trial of the hemopurifier. this trial is designed for patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® (pembrolizumab) or opdivo® (nivolumab) (aemd-2022-06 hemopurifier study).
AEMD Ratings Summary
AEMD Quant Ranking